Skip to content

Breathing Intervention for Cardiac Anxiety

Anatomical and Psychophysiological Substrates of Interoception

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02916550
Enrollment
12
Registered
2016-09-27
Start date
2016-09-30
Completion date
2023-05-31
Last updated
2023-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation, Implantable Cardioverter Defibrillator

Brief summary

This study examines the impact of a breathing training intervention on cardiorespiratory sensations and anxiety in adults with cardiac arrhythmias.

Detailed description

Patients with cardiac arrhythmias develop increased rates of anxiety and depression. Atrial arrhythmias, such as paroxysmal atrial fibrillation (AF), and ventricular arrhythmias, such as those with implantable cardioverter defibrillators (ICD) are particularly at risk. While ICDs can be life saving, many patients (including those without prior psychiatric illness) develop elevated rates of anxiety and depression, particularly after receiving discharges (shocks) from the device. Treatments involving modulation of the breath have been shown to improve both psychological and cardiac outcomes in patients with AF. Since breathing modulation alters sympathetic balance, this may be a mechanism of the therapeutic effect. This study examines the impact of a breathing training intervention on cardiorespiratory sensations and anxiety in adults with atrial and ventricular cardiac arrhythmias.

Interventions

BEHAVIORALBreathing exercise

Participants will perform a paced breathing intervention (slow breathing) prompted by pseudorandomized remote reminders (scheduled reminders plus non scheduled reminders), through cellular phone application.

Sponsors

University of Arizona
CollaboratorOTHER
Laureate Institute for Brain Research, Inc.
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Age 18 to 80 * BMI 17 to 35 * Proficient in English language * Paroxysmal atrial fibrillation or ventricular fibrillation or frequent premature atrial/ventricular contractions

Exclusion criteria

* No telephone access * Active suicidal ideation with intent or plan * Active drug or alcohol dependence, or active binge drinking within the last month * Cardiovascular instability, as evidenced any of the following: 1. New York Heart Association (NHYA) heart failure class IV (i.e., unable to carry on any physical activity without discomfort, symptoms of heart failure at rest, increased discomfort with any physical activity is undertaken) 2. American College of Cardiology/American Heart Association congestive heart failure stage D (i.e., heart failure symptoms at rest, receiving end of life care). 3. Unstable angina or exercise induced angina 4. Persistent atrial fibrillation * Pacemakers or combined pacemaker/ICDs will be excluded * Presence of unstable cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, or metabolic disease; or any other condition that, in the opinion of the investigator, would make participation not be in the best interest (e.g., compromise the well-being) of the subject or that could prevent, limit, or confound the protocol-specified assessments.

Design outcomes

Primary

MeasureTime frameDescription
Cardiac anxiety1 monthAssessed via the Cardiac Anxiety Questionnaire

Secondary

MeasureTime frameDescription
Disability1 monthMeasured by the WHO Disability Assessment Scale (WHODAS)
Wellbeing1 monthNIH Patient Reported Outcome Measurement Information System (PROMIS)
ICD anxiety1 monthFlorida Shock Anxiety Scale
Arrhythmia burden1 monthPresence of atrial fibrillation or ICD shocks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026